Pfizer Oncology is committed to pursuing innovative treatments that will have a meaningful impact on people living with cancer. As a leader in oncology, Pfizer Oncology is focused on helping to redefine life with cancer.

By maximizing our internal scientific resources and collaborating with other companies and government and academic institutions, as well as non-profit and professional organizations, we bring together the brightest and most enterprising minds to take on the toughest cancers, helping accelerate breakthrough treatments to patients around the world.

10 APPROVED ONCOLOGY MEDICINES
that treat a diverse array of solid tumors and hematologic cancers:

- Merkel Cell Carcinoma
- Lung Cancer
- Kidney Cancer
- Prostate Cancer
- Gastrointestinal Stromal Tumors
- Leukemia
- Breast Cancer
- Neuroendocrine Tumors

7 ONCOLOGY MEDICINES
launched since 2011

7 BREAKTHROUGH THERAPY DESIGNATIONS SINCE 2013
in metastatic breast cancer, non-small cell lung cancer, acute lymphoblastic leukemia, acute myeloid leukemia and Merkel cell carcinoma

MORE THAN 580K
patients treated with approved Pfizer Oncology therapies since 2006

$4.563 BILLION IN REVENUE
generated from oncology medicines in 2016
Our Partnerships

SCIENTIFIC AND ACADEMIC PARTNERSHIPS
Pfizer Oncology believes that great science comes through collaboration. Our Centers for Therapeutic Innovation demonstrate our deep commitment to establishing close collaborations with leading academic medical centers, U.S. government agencies, foundations and other industry partners to find new ways to translate ground-breaking research into new and important therapies for patients.

- Since 2014, Pfizer has provided more than $35 million to unique breast cancer research grant partnerships.

CANCER COMMUNITY PARTNERSHIPS
- We know that cancer is a disease that no one should fight alone. That’s why Pfizer Oncology not only aims to bring valuable treatments to patients, but also to cultivate community relationships for the collective good.
- Together with the broader cancer community, we support patients through numerous sponsored initiatives focused on education and empowerment, supporting caregivers and loved ones, elevating public awareness of various cancers, and rallying local and global communities to support cancer patients.

Our People and Places

GLOBAL REACH

4,000
Pfizer Oncology Employees Worldwide

LEADERSHIP

Liz Barrett
Global President and General Manager
Pfizer Oncology

Mace Rothenberg, MD
Chief Development Officer, Oncology
Pfizer Global Product Development

Chris Boshoff, MD, PhD
Senior Vice President and Head of Immuno-Oncology, Translational Oncology and Early Development
Pfizer Global Product Development

Bob Abraham, PhD
Senior Vice President and Group Head, Oncology - Rinat R&D